Search details
1.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
N Engl J Med
; 387(23): 2113-2125, 2022 12 08.
Article
in English
| MEDLINE | ID: mdl-36477031
2.
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
Int J Cancer
; 154(10): 1760-1771, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38296842
3.
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Cancer
; 130(9): 1673-1683, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38198485
4.
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
Int J Cancer
; 153(2): 389-398, 2023 07 15.
Article
in English
| MEDLINE | ID: mdl-36843260
5.
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
Int J Cancer
; 152(12): 2493-2502, 2023 06 15.
Article
in English
| MEDLINE | ID: mdl-36843274
6.
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Ann Surg Oncol
; 30(1): 573-586, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36203067
7.
The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
Int J Cancer
; 150(5): 816-824, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-34605003
8.
Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
Int J Cancer
; 150(2): 317-326, 2022 01 15.
Article
in English
| MEDLINE | ID: mdl-34520567
9.
Neoantigen landscape dynamics during human melanoma-T cell interactions.
Nature
; 536(7614): 91-5, 2016 08 04.
Article
in English
| MEDLINE | ID: mdl-27350335
10.
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
Ann Intern Med
; 174(5): 641-648, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33587686
11.
Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
Br J Cancer
; 124(7): 1199-1206, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33462360
12.
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Br J Cancer
; 124(7): 1222-1230, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33495600
13.
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Cancer Immunol Immunother
; 70(11): 3123-3135, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-33774697
14.
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.
Ann Surg Oncol
; 28(2): 1130-1141, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-32761328
15.
Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice.
Gynecol Oncol
; 161(1): 202-210, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33514483
16.
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.
J Med Genet
; 57(5): 316-321, 2020 05.
Article
in English
| MEDLINE | ID: mdl-30291219
17.
The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review.
Int J Cancer
; 146(6): 1479-1489, 2020 03 15.
Article
in English
| MEDLINE | ID: mdl-31583684
18.
Real-world outcomes of advanced melanoma patients not represented in phase III trials.
Int J Cancer
; 147(12): 3461-3470, 2020 12 15.
Article
in English
| MEDLINE | ID: mdl-32559817
19.
Malignant pheochromocytoma and paraganglioma: management options.
Curr Opin Oncol
; 32(1): 20-26, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31599769
20.
Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
Q J Nucl Med Mol Imaging
; 64(3): 250-264, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32744039